Overall, while depatux-m showed some activity in specific subgroups, it did not confer a survival advantage in the broader EGFR-amp glioblastoma population, suggesting that depatux-m may offer clinical benefit in cancers with high EGFR expression, warranting further investigation in targeted patient populations. Here, EGFR is linked to cancer.